Lynparza Tablets 100mg, 150mg Clinical Experience Investigation (All Case Investigation) in Patients With Platinum-sensitive Relapsed Ovarian Cancer
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 21 Nov 2018
At a glance
- Drugs Olaparib (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions
- Sponsors AstraZeneca
- 31 Aug 2018 Biomarkers information updated
- 14 Aug 2018 Status changed from recruiting to active, no longer recruiting.
- 07 Jun 2018 Status changed from not yet recruiting to recruiting.